FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Fudan University
Gruppo Oncologico del Nord-Ovest
University of Chicago
Xijing Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tongji Hospital
Hoffmann-La Roche
China Meitan General Hospital
Nanjing Chia-tai Tianqing Pharmaceutical
Peking University Cancer Hospital & Institute
Hebei Medical University
Fudan University
Hebei Medical University
National Cancer Institute (NCI)
Nanjing Medical University
Sanofi
Sanofi